I am very happy with the growing recognition of personalized medicine in the treatment of multiple sclerosis (MS).
Our research highlights the importance of personalized treatment plans for natalizumab and ocrelizumab, offering several benefits:
▪ They lower the burden of treatments, cutting down hospital visits by 30-40% on average.
▪ They reduce the risk of adverse events associated with MS treatments.
▪ They can lower healthcare costs related to MS management.
Continued research into personalized treatment in MS is essential, and fortunately, several promising studies are underway:
▪ Liza Gelissen of the Amsterdam UMC – MS Centrum Amsterdam is leading the SUPERNEXT study, a follow-up on personalized extended intervals of natalizumab, allowing participants to extend their treatment intervals further.
▪ Stefan van den Berg from Sanquin is developing a pharmacokinetic model to more accurately estimate natalizumab treatment intervals.
▪ Laura Hogenboom of the Amsterdam UMC – MS Centrum Amsterdam is conducting the BLOOMS study, where patients using ocrelizumab receive extended intervals based on B-cell counts.
I am very grateful for the excellent guidance during my PhD from Joep Killestein, Zoé van Kempen, Bernard Uitdehaag, and Theo Rispens, and for the support from our sponsors: Stichting MS Research, Hersenstichting, Innovatiefonds Zorgverzekeraars, Stichting Treatmeds, and our collaboration with Sanquin.
Let’s continue pushing the boundaries to influence clinical practice, further paving the road towards a personalized approach.
Link thesis: https://lnkd.in/ekheAQrF.
Alyssa Toorop won de prijs voor beste proefschrift en Carla Rodriguez Mogeda won de derde prijs. De prijzen werden uitgereikt tijdens de MS-onderzoeksdagen van Stichting MS Research (afgelopen 15 en 16 mei in Genk, België). Lees meer: https://lnkd.in/g6BsiTD8